1-20 of 63
Raymonde Busch
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara Eichhorst, MD, Anna Maria Fink, MD, Raymonde Busch, Gabor Kovacs, MD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof. Dr., Michael G Kiehl, MD, Martin Soekler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg R.A. Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, MD PhD, Clemens-Martin Wendtner, MD, Wolfram Klapper, MD, Karl Anton Kreuzer, Prof. Dr. MD, Stephan Stilgenbauer, MD PhD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2014) 124 (21): 19.
https://doi.org/10.1182/blood.V124.21.19.19
Published: 2014
Journal Articles

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Martin Weisser, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, Giuseppe Palermo, Tri Quang Nguyen, Xiaoyan Shi, Susanna Y. Stinson, Nancy Yu, Annika Dufour, Tadeusz Robak, Galina N. Salogub, Anna Dmoszynska, Philippe Solal-Celigny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Loree Larratt, Viktor A. Rossiev, Isabelle Bence-Bruckler, Christian H. Geisler, Marco Montillo, Kirsten Fischer, Anna-Maria Fink, Michael Hallek, Johannes Bloehdorn, Raymonde Busch, Axel Benner, Hartmut Döhner, Nancy Valente, Michael K. Wenger, Stephan Stilgenbauer, David Dornan
Journal: Blood
Blood (2014) 124 (3): 420–425.
https://doi.org/10.1182/blood-2013-12-538975
Published: 2014
Includes: Supplemental data
Journal Articles

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia

Clinical Trials & Observations
Natali Pflug, Jasmin Bahlo, Tait D. Shanafelt, Barbara F. Eichhorst, Manuela A. Bergmann, Thomas Elter, Kathrin Bauer, Gebhart Malchau, Kari G. Rabe, Stephan Stilgenbauer, Hartmut Döhner, Ulrich Jäger, Michael J. Eckart, Georg Hopfinger, Raymonde Busch, Anna-Maria Fink, Clemens-Martin Wendtner, Kirsten Fischer, Neil E. Kay, Michael Hallek
Journal: Blood
Blood (2014) 124 (1): 49–62.
https://doi.org/10.1182/blood-2014-02-556399
Published: 2014
Includes: Supplemental data
Journal Articles

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Clinical Trials & Observations
Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, Hartmut Döhner
Journal: Blood
Blood (2014) 123 (21): 3247–3254.
https://doi.org/10.1182/blood-2014-01-546150
Published: 2014
Includes: Supplemental data
Journal Articles

High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial

Johannes Bloehdorn, MD, Martin Sill, PhD, Christian Langer, MD, Axel Benner, Dipl.Stat., Thorsten Zenz, MD, Andreas Bühler, MD, Raymonde Busch, PhD, Peter Dreger, MD, Ulrich Jäger, MD, Michael Hallek, M.D. Ph.D., Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 1618.
https://doi.org/10.1182/blood.V122.21.1618.1618
Published: 2013
Journal Articles

Telomere Length and Treatment Outcome In Chronic Lymphocytic Leukemia: Results From The CLL8 Trial

Billy Michael Chelliah Jebaraj, PhD, Raymonde Busch, PhD, Thorsten Zenz, MD, Andreas Bühler, MD, Dirk Winkler, MD, Andrea Schnaiter, MD, Jennifer Edelmann, MD, Daniel Mertens, PhD, Sebastian Böttcher, MD, Michael Kneba, MD, Ulrich Jäger, MD, Michael K Wenger, MD, Guenter Fingerle-Rowson, MD PhD, Clemens Wendtner, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 671.
https://doi.org/10.1182/blood.V122.21.671.671
Published: 2013
Journal Articles

Overall Survival In Early Stage Chronic Lymphocytic Leukemia Patients With Treatment Indication Due To Disease Progression: Follow-Up Data Of The CLL1 Trial Of The German CLL Study Group (GCLLSG)

Manuela A. Bergmann, MD, Raymonde Busch, PhD, Barbara Eichhorst, MD, Andreas Buehler, MD, Norbert Fischer, MD, Michael J Eckart, MD, Ursula Vehling-Kaiser, MD, Ulrich Jäger, MD, Georg Hopfinger, MD, Clemens Wendtner, MD, Kirsten Fischer, MD, Bertold Emmerich, MD, Hartmut Döhner, MD, Michael Hallek, M.D. Ph.D., Stephan Stilgenbauer, MD
Journal: Blood
Blood (2013) 122 (21): 4127.
https://doi.org/10.1182/blood.V122.21.4127.4127
Published: 2013
Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Valentin Goede, MD, Kirsten Fischer, MD, Raymonde Busch, PhD, Anja Engelke, Barbara Eichhorst, MD, Clemens M Wendtner, MD, Tatiana Chagorova, MD, Javier De la Serna, MD, PhD, Marie-Sarah Dilhuydy, MD, Stephen Opat, MD, Carolyn J. Owen, MD, FRCPC, Olga Samoylova, MD, Karl-Anton Kreuzer, MD, Anton W Langerak, PhD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, MD, Michael Hallek, MD
Journal: Blood
Blood (2013) 122 (21): 6.
https://doi.org/10.1182/blood.V122.21.6.6
Published: 2013
Journal Articles

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial

Carmen D Schweighofer, MD, Florence Cymbalista, MD, Carolin Müller, MD, Raymonde Busch, PhD, Raphael Porcher, PhD, Petra Langerbeins, MD, Bruno Cazin, MD, Anna-Maria Fink, MD, Brigitte Dreyfus, MD, Stefan Ibach, Stéphane Leprêtre, MD, Kirsten Fischer, MD, Ursula Vehling-Kaiser, MD, Barbara Eichhorst, MD, Manuela A. Bergmann, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Veronique Leblond, MD, Michael Hallek, MD, Vincent Levy, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 524.
https://doi.org/10.1182/blood.V122.21.524.524
Published: 2013
Journal Articles

Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Analysis Of The CLL10 Trial, An International, Randomized Study Of The German CLL Study Group (GCLLSG)

Barbara Eichhorst, MD, Anna-Maria Fink, MD, Raymonde Busch, PhD, Elisabeth Lange, MD, Hubert Köppler, Michael Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Marek Trneny, MD, Ph.D., Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens Wendtner, MD, Wolfram Klapper, Karl-Anton Kreuzer, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Michael Hallek, MD
Journal: Blood
Blood (2013) 122 (21): 526.
https://doi.org/10.1182/blood.V122.21.526.526
Published: 2013
Journal Articles

NOTCH1 , SF3B1 , and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Brief Report
Andrea Schnaiter, Peter Paschka, Marianna Rossi, Thorsten Zenz, Andreas Bühler, Dirk Winkler, Mario Cazzola, Konstanze Döhner, Jennifer Edelmann, Daniel Mertens, Sabrina Kless, Silja Mack, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood
Blood (2013) 122 (7): 1266–1270.
https://doi.org/10.1182/blood-2013-03-488197
Published: 2013
Includes: Supplemental data
Journal Articles

TP53 , SF3B1 , and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

Brief Report
Peter Dreger, Andrea Schnaiter, Thorsten Zenz, Sebastian Böttcher, Marianna Rossi, Peter Paschka, Andreas Bühler, Sascha Dietrich, Raymonde Busch, Matthias Ritgen, Donald Bunjes, Matthias Zeis, Michael Stadler, Lutz Uharek, Christof Scheid, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood
Blood (2013) 121 (16): 3284–3288.
https://doi.org/10.1182/blood-2012-11-469627
Published: 2013
Includes: Supplemental data
Journal Articles

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Jennifer Edelmann, Karlheinz Holzmann, Florian Miller, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Lars Bullinger, Michael W. M. Kühn, Andreas Gerhardinger, Johannes Bloehdorn, Ina Radtke, Xiaoping Su, Jing Ma, Stanley Pounds, Michael Hallek, Peter Lichter, Jan Korbel, Raymonde Busch, Daniel Mertens, James R. Downing, Stephan Stilgenbauer, Hartmut Döhner
Journal: Blood
Blood (2012) 120 (24): 4783–4794.
https://doi.org/10.1182/blood-2012-04-423517
Published: 2012
Includes: Supplemental data
Journal Articles

Alemtuzumab Plus Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allogeneic Transplantation in Ultra High-Risk CLL: Updated Results From a Phase II Study of the Gcllsg and fcgcll/MW

Stephan Stilgenbauer, MD, Florence Cymbalista, MD, PhD, Veronique Leblond, Alain Delmer, MD, Silja Mack, MSc, Andreas Bühler, Dirk Winkler, Thorsten Zenz, MD, Raymonde Busch, Stefan Ibach, Sylvain Choquet, MD, Dartigeas Caroline, Bruno Cazin, Dr., Olivier Tournilhac, MD, PhD, Till M Seiler, MD, Katja Zirlik, Jürgen Alt, MD, Martin Sökler, MD, Johannes Schetelig, MD, Peter Dreger, MD, Michael Hallek, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2012) 120 (21): 716.
https://doi.org/10.1182/blood.V120.21.716.716
Published: 2012
Journal Articles

The Use of Chemoimmunotherapy Improves the Outcome of Patients with Chronic Lymphocytic Leukaemia (CLL) – a Metaanalysis of Five Trials of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Susanne Isfort, MD, Jasmin Bahlo, Raymonde Busch, Petra Langerbeins, MD, Anna-Maria Fink, MD, Valentin Goede, MD, Thomas Elter, MD, Manuela A. Bergmann, MD, Martina Beate Stauch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Michael Hallek, MD PhD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2012) 120 (21): 3936.
https://doi.org/10.1182/blood.V120.21.3936.3936
Published: 2012
Journal Articles

Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Kirsten Fischer, MD, Jasmin Bahlo, Anna- Maria Fink, MD, Raymonde Busch, Sebastian Böttcher, MD, Jiri Mayer, MD, Peter Dreger, MD, Christian Maurer, Anja Engelke, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD
Journal: Blood
Blood (2012) 120 (21): 435.
https://doi.org/10.1182/blood.V120.21.435.435
Published: 2012
Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Stephan Stilgenbauer, MD, Raymonde Busch, Andrea Schnaiter, MD, Peter Paschka, Marianna Rossi, Konstanze Döhner, Thorsten Zenz, MD, Andreas Bühler, Dirk Winkler, Jennifer Edelmann, MD, Daniel Mertens, PhD, Lars Bullinger, MD, PhD, Sabrina Kless, Silja Mack, MSc, Sebastian Böttcher, MD, Matthias Ritgen, Michael Kneba, MD, PhD, Ulrich Jäger, MD, Peter Lichter, Nancy Patten, PhD., Michael K. Wenger, Myriam Mendila, MD, Gunter Fingerle-Rowson, MD, PhD, Mario Cazzola, Clemens Wendtner, Anna Maria Fink, MD, Kirsten Fischer, MD, Michael Hallek, MD, Hartmut Döhner
Journal: Blood
Blood (2012) 120 (21): 433.
https://doi.org/10.1182/blood.V120.21.433.433
Published: 2012
Journal Articles

NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg

Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Mario Cazzola, Konstanze Döhner, MD, Jennifer Edelmann, MD, Andreas Bühler, MD, Sabrina Kless, Daniel Mertens, PhD, Raymonde Busch, Silja Mack, MSc, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2012) 120 (21): 710.
https://doi.org/10.1182/blood.V120.21.710.710
Published: 2012
Journal Articles

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial

Peter Dreger, Hartmut Döhner, Fabienne McClanahan, Raymonde Busch, Matthias Ritgen, Hildegard Greinix, Anna-Maria Fink, Wolfgang Knauf, Michael Stadler, Michael Pfreundschuh, Ulrich Dührsen, Günter Brittinger, Manfred Hensel, Johannes Schetelig, Dirk Winkler, Andreas Bühler, Michael Kneba, Norbert Schmitz, Michael Hallek, Stephan Stilgenbauer
Journal: Blood
Blood (2012) 119 (21): 4851–4859.
https://doi.org/10.1182/blood-2011-09-378505
Published: 2012
Includes: Supplemental data
Journal Articles

Prognostic Impact of Biallelic Versus Monoallelic Deletion 13q and the Proportion of Cells with Deletion 13q within the CLL8 Trial of the German CLL Study Group (GCLLSG)

Dirk Winkler, MD, Raymonde Busch, Andreas Buehler, MD, Michael K. Wenger, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2011) 118 (21): 2841.
https://doi.org/10.1182/blood.V118.21.2841.2841
Published: 2011